Lyell Immunopharma, Inc. financial data

Symbol
LYEL on Nasdaq
Location
201 Haskins Way, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 793 % -48.9%
Debt-to-equity 27.2 % +76.9%
Return On Equity -96.7 % -179%
Return On Assets -76 % -153%
Operating Margin -836K % -143%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21.2M shares -92.4%
Common Stock, Shares, Outstanding 19.3M shares -92.5%
Entity Public Float 306M USD -53.2%
Common Stock, Value, Issued 2K USD -92.3%
Weighted Average Number of Shares Outstanding, Basic 18.3M shares +42.6%
Weighted Average Number of Shares Outstanding, Diluted 18.3M shares +42.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 41K USD -34.9%
Research and Development Expense 28.2M USD -28.7%
General and Administrative Expense 49M USD -3.25%
Operating Income (Loss) -343M USD -57.9%
Nonoperating Income (Expense) 17.2M USD +31.4%
Net Income (Loss) Attributable to Parent -326M USD -59.6%
Earnings Per Share, Basic 0 USD/shares +38.8%
Earnings Per Share, Diluted 0 USD/shares +38.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 124M USD +23.2%
Marketable Securities, Current 196M USD -42.4%
Assets, Current 328M USD -27.1%
Property, Plant and Equipment, Net 36.7M USD -58.3%
Operating Lease, Right-of-Use Asset 19.9M USD -45.7%
Other Assets, Noncurrent 2.55M USD -49.7%
Assets 408M USD -34.1%
Accounts Payable, Current 2.57M USD -28.6%
Liabilities, Current 31.9M USD -4.88%
Operating Lease, Liability, Noncurrent 44.3M USD -13.9%
Other Liabilities, Noncurrent 2.68M USD -24.8%
Liabilities 78.8M USD -10.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 201K USD -73.6%
Retained Earnings (Accumulated Deficit) -1.48B USD -28.2%
Stockholders' Equity Attributable to Parent 329M USD -38%
Liabilities and Equity 408M USD -34.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -54.7M USD -30.3%
Net Cash Provided by (Used in) Financing Activities 27K USD
Net Cash Provided by (Used in) Investing Activities 69.5M USD +216%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 19.3M shares -92.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 14.7M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 125M USD +24.4%
Deferred Tax Assets, Valuation Allowance 359M USD +44.7%
Deferred Tax Assets, Gross 366M USD +39.1%
Operating Lease, Liability 53.1M USD -9.39%
Payments to Acquire Property, Plant, and Equipment 246K USD +720%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -326M USD -61.5%
Lessee, Operating Lease, Liability, to be Paid 65.1M USD -13.3%
Property, Plant and Equipment, Gross 119M USD -23%
Operating Lease, Liability, Current 8.79M USD +23.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.3M USD +9.27%
Lessee, Operating Lease, Liability, to be Paid, Year One 13M USD +9.28%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 12M USD -27.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 13M USD +3.47%
Deferred Tax Assets, Operating Loss Carryforwards 176M USD +32.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.66M USD +815%
Lessee, Operating Lease, Liability, to be Paid, Year Four 10.4M USD -19.6%
Additional Paid in Capital 1.81B USD +7.41%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 3.44M USD -31.5%
Deferred Tax Assets, Net of Valuation Allowance 6.92M USD -53.7%
Share-based Payment Arrangement, Expense 24.3M USD -27.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%